LP interview: Allianz Capital Partners
In approaching Asian private equity, Allianz Capital Partners combines the classic conservatism of an insurance investor with a seasoned understanding of how to assess – and perhaps not over-respond – to risk
Emerging markets offer significant growth opportunities tempered by a plethora of risks. What is currently happening in China’s technology sector isn’t necessarily dissimilar to the blips – some...
Co-Stone leads $43m round for China biosynthesis player
Co-Stone Capital Management has led a CNY 300m (USD 43m) Series B round for Readline, a Shenzhen-based company that specialises in synthetic biology.
Australia’s Heal Partners closes debut fund on $137m
Australia’s Heal Partners, a health, education, and lifestyle-focused venture capital firm, has closed its first fund on AUD 200m (USD 137m). The target was AUD 100m.
US regulator gets access to Chinese audits
The threat of delisting that has haunted Chinese companies that trade on US exchanges appears to have receded after the US regulators announced they had gained full access to the audits of these companies for the first time.